Drug Profile
WP 1066
Alternative Names: WP-1066Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Emory University; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center; WPD Pharmaceuticals
- Class Amides; Antineoplastics; Halogenated hydrocarbons; Nitriles; Pyridines; Small molecules
- Mechanism of Action Hypoxia-inducible factor 1 inhibitors; Immunostimulants; Proto oncogene protein c-myc inhibitors; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glioma
Highest Development Phases
- Phase I/II Brain metastases; Glioblastoma; Pancreatic cancer
- Preclinical Brain cancer
- No development reported Acute myeloid leukaemia; Eye neoplasms; Glioma; Medulloblastoma
Most Recent Events
- 27 Mar 2024 Phase-I development in Brain metastases (In adolescents, In children, Recurrent, Second-line therapy or greater, In adults) is ongoing in USA (PO)
- 27 Mar 2024 Preclinical development in Brain-cancer is ongoing in USA
- 24 Jan 2024 Moleculin Biotech plans phase II study for Brain cancers and Diffuse intrinsic pontine glioma (in children, In infants, In neonates) in second half of 2024